706 860
results from the national cancer data base. Eur Urol 2015;68:
768–74
.
[4]
Leyh-Bannurah SR, Gazdovich S, Budaus L, et al. Population-based external validation of the updated 2012 Partin tables in contem- porary North American prostate cancer patients. Prostate 2016; 77:105–13.
[5]
Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol 2012;188:2219–24.
[6]
Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long- term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012;380:2018–27.
[7]
Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow- up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol 2014;66:243–50.
[8]
Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181:956–62.
[9]
Gandaglia G, Cozzarini C, Mottrie A, et al. The role of radiotherapy after radical prostatectomy in patients with prostate cancer. Curr Oncol Rep 2015;17:53.
[10]
van Stam MA, Aaronson NK, Pos FJ, et al. The effect of salvage radiotherapy and its timing on the health-related quality of life of prostate cancer patients. Eur Urol 2016;70:751–7.
[11]
Suardi N, Gallina A, Lista G, et al. Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatec- tomy. Eur Urol 2014;65:546–51.[12]
Gandaglia G, Lista G, Fossati N, et al. Non-surgically related causes of erectile dysfunction after bilateral nerve-sparing radical pros- tatectomy. Prostate Cancer Prostatic Dis 2016;19:185–90.
[13]
Fossati N, Karnes RJ, Boorjian SA, et al. Long-term impact of adjuvant versus early salvage radiation therapy in pT3N0 prostate cancer patients treated with radical prostatectomy: results from a multi-institutional series. Eur Urol 2017;71:886–93.
[14]
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.[15]
Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collabor- ation’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.[16]
Ghadjar P, Hayoz S, Bernhard J, et al. Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemi- cally recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10. J Clin Oncol 2015;33:4158–66.[17]
Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate- specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomized, multicentre, open-label phase 3 trial. Lancet Oncol 2016;17:747–56.[18]
Shipley WU, Pugh SL, Lukka HR, et al. NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation ther- apy (RT) following radical prostatectomy (RP) and an elevated PSA. J Clin Oncol 2016;34(Suppl 2S):abstr 3.
[19]
Abdollah F, Karnes RJ, Suardi N, et al. Impact of adjuvant radio- therapy on survival of patients with node-positive prostate cancer. J Clin Oncol 2014;32:3939–47.[20]
Briganti A, Karnes RJ, Da Pozzo LF, et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol 2011;59:832–40.[21]
Kaplan JR, Kowalczyk KJ, Borza T, et al. Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy. BJU Int 2013;111:1208–14.[22]
Rusthoven CG, Carlson JA, Kavanagh BD. External validation of the benefit of adjuvant radiotherapy for pathologic N1M0 prostate cancer. J Clin Oncol 2015;33:1987–8.
[23]
Tilki D, Preisser F, Tennstedt P, et al. Adjuvant radiation therapy is associated with better oncological outcome compared with sal- vage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy. BJU Int 2017;119:717–23.[24]
Wong AT, Schwartz D, Osborn V, Safdieh J, Weiner J, Schreiber D. Adjuvant radiation with hormonal therapy is associated with improved survival in men with pathologically involved lymph nodes after radical surgery for prostate cancer. Urol Oncol 2016; 34:529.e15-29.[25]
Budiharto T, Perneel C, Haustermans K, et al. A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. Radiother Oncol 2010;97:474–9.[26]
D’Amico AV, Chen MH, Sun L, et al. Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. BJU Int 2010;106:1618–22.[27]
Detti B, Scoccianti S, Cassani S, et al. Adjuvant and salvage radio- therapy after prostatectomy: outcome analysis of 307 patients with prostate cancer. J Cancer Res Clin Oncol 2013;139:147–57.[28]
Jereczek-Fossa BA, Zerini D, Vavassori A, et al. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy. Int J Radiat Oncol Biol Phys 2009;74:115–25.
[29]
Mishra MV, Scher ED, Andrel J, et al. Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse path- ologic features: comparative analysis of long-term outcomes. Am J Clin Oncol 2015;38:55–60.
[30]
Ost P, De Troyer B, Fonteyne V, Oosterlinck W, De Meerleer G. A matched control analysis of adjuvant and salvage high-dose post- operative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011;80:1316–22.[31]
Abdollah F, Suardi N, Cozzarini C, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013; 63:998–1008.
[32]
Den RB, Yousefi K, Trabulsi EJ, et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol 2015;33: 944–51.[33]
Gandaglia G, Karakiewicz PI, Briganti A, et al. Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria. Int J Urol 2015;22:89–95.[34]
Van der Kwast TH, Bolla M, Van Poppel H, et al. Identification of patients with prostate cancer who benefit from immediate post- operative radiotherapy: EORTC 22911. J Clin Oncol 2007;25: 4178–86.[35]
Ross AE, Den RB, Yousefi K, et al. Efficacy of post-operative radia- tion in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer Prostatic Dis 2016;19:277–82.[36]
Zhao SG, Chang SL, Spratt DE, et al. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol 2016;17:1612–20.[37]
Bottke D, Golz R, Storkel S, et al. Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis. Eur Urol 2013;64:193–8.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 6 8 9 – 7 0 9
706